Background. The provision of starter packs for human immunodeficiency virus postexposure prophylaxis (PEP) is practiced in many settings to facilitate rapid initiation by nonexperts and encourage adherence. However, the impact of starter packs on PEP completion rates has not been systematically assessed. We systematically reviewed the evidence on outcomes associated with starter packs for PEP compared to full prescriptions.
Postexposure prophylaxis (PEP) with antiretroviral drugs is a well-established and widely used intervention to prevent human immunodeficiency virus (HIV) infection. While the recommended duration of PEP (28 days) is generally consistent across guidelines, prescribing practices vary. In some settings the full 28-day course is provided at first visit, whereas in other settings an initial course of 3-5 days of antiretroviral drugs (commonly referred to as starter packs) is provided, with individuals required to return during 1 or more interim visits to collect the rest of their PEP course.
Reported reasons for using starter packs include facilitating rapid initiation of PEP by nonexperts [1] , encouraging adherence [2] , assessing toxicity and providing additional counseling [3] , and pacifying anxious individuals with a view to discontinuing at next visit [4] . PEP starter packs may also be provided to highrisk individuals to take in case of subsequent exposure [5] . However, the impact of PEP starter packs on completion rates has not been systematically assessed.
To inform future World Health Organization (WHO) guidance on the provision of PEP, we systematically reviewed the evidence on outcomes associated with different PEP prescribing practices.
METHODS
Using a predefined protocol including a sensitive search strategy, 2 investigators (N. F., C. I.), working independently, scanned all abstracts, assessed potentially eligible studies as full text, and extracted outcomes in duplicate; in case of disagreement, a third investigator (Z. S.) was consulted. , and whether the regimen included zidovudine or tenofovir. Point estimates and 95% confidence intervals (CIs) were calculated for the proportion of individuals reaching each step in the cascade of care, from eligibility determination to attendance of follow-up visit, and data were pooled using random-effects meta-analysis, following appropriate data transformation. The quality of the evidence was assessed using GRADE [6] . All analyses were conducted using Stata version 12.0 (StataCorp, College Station, Texas).
RESULTS

Study Characteristics
From an initial screen of 3259 titles (Supplementary Appendix), 54 studies were taken through for review: 37 studies (5997 PEP initiations) across 17 countries reported outcome data for individuals provided with a PEP starter pack at first visit [2, 4, 5, , and 17 studies (5717 initiations) across 9 countries reported outcome data for individuals provided with a full PEP course [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] . Studies reporting on starter packs included 3 randomized controlled trials (RCTs) and 34 observational cohorts, whereas studies on full prescriptions included 2 RCTs and 15 observational cohorts. None of the RCTs were designed to specifically assess the impact of starter packs (3 assessed adherence support interventions [7, 28, 43] and 2 assessed drug safety [38, 57] ). Only 1 cohort study that reported PEP outcomes following sexual assault in South Africa provided a direct comparison of completion rates before and after a policy change from starter packs to the full 28-day PEP [58] . The provision of a full course of PEP at initial visit was more common for occupational exposures (35.1% vs 17.7%), but differences were not significant (P = .2). There were no apparent differences in study characteristics with respect to other exposures, population, or number or type of drugs used. The overall quality of the evidence contributing to the systematic review was rated as very low. Most data were contributed by small observational studies, leading to imprecision in the pooled estimates for all outcomes, and no direct contemporaneous comparisons were available for analysis.
Review Findings
Where starter packs were given, the duration of the first course varied from 1 day to 14 days, with the most common course being a 3-day (47% of studies) or 5-day course (17%). Details of included studies are provided in the Supplementary Appendix.
Overall, outcomes were better when participants were offered a full 28-day course of PEP, with fewer refusals (11 A similar proportion of people had PEP discontinued either because of adverse drug reactions or because it was considered unnecessary (Table 1 ). In the one study that assessed PEP completion rates before and after a policy change from starter packs to full prescriptions, patients given a full course of drugs on first visit were significantly more likely than those given a starter pack with follow-up appointments to have taken PEP for 28 days (71% vs 29%, respectively) [58] .
DISCUSSION
This review assessed outcomes for starter packs compared with full prescriptions of PEP across 54 studies, including 5 RCTs and 1 pre-post study, and found that starter packs did not improve adherence to PEP, and may result in lower adherence and completion rates. Starter packs may have a role in specific clinical settings, such as emergency departments, that are not adequately prepared to support patients in need of PEP and instead provide starter packs as part of the referral process. However, a recent study from the United States that reported low rates of PEP completion following referral from emergency departments suggested that patients presenting to emergency departments should be provided with extended or full courses of PEP to provide patients an opportunity to take PEP even if they do not adhere to scheduled clinic follow-up [9] . In South Africa, long distances and travel costs have been suggested as a reason why women are unable to return to care to receive a full course of PEP following sexual assault [13] , and preference has been expressed to receive a full course of treatment at first visit [59] .
Strengths of this review include a broad search strategy that allowed for the analysis of >11 000 PEP initiations across a range of settings and exposures. The main limitation of this review is the lack of high-quality studies directly comparing different prescribing practices, and there may be important differences in patient and program characteristics between studies that provided starter packs and those that provided full prescriptions. We were only able to identify 1 study that compared the 2 approaches within the same cohort; this was a before-after study in which multiple programmatic changes were made during the reporting period. This reflects a general lack of high-quality evidence to support policy for PEP [60] . High-quality studies that directly compare starter packs and full prescriptions are needed.
The latest WHO guidelines for antiretroviral therapy recommend that nonphysician health workers can initiate antiretroviral therapy, and this recommendation can be extended to PEP. The use of less-toxic drugs and a simplified approach to risk stratification will facilitate PEP provision such that the use of starter packs to support PEP provision by nonspecialists may no longer be relevant. The findings of this review suggest that while starter packs may be a useful strategy in specific settings, there is no evidence to suggest they result in improved outcomes. Although referrals for counseling and advice may still be needed, PEP providers should consider providing a full 28-day course of drugs at the outset. These findings support the recommendation by WHO to provide a full 28-day course of PEP at initial presentation [61] .
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